Each year ovarian cancer experts from across the nation gather at the Society of Gynecologic Oncology Conference. Stephanie Blank, MD, Director of Gynecologic Oncology, Mt. Sinai Health System, will report back from the conference on what the research presented there means for patients.

1. Ovarian Cancer: What’s New
Stephanie V. Blank, MD
Professor, Department of Obstetrics, Gynecology and Reproductive
Science, Icahn School of Medicine at Mount Sinai
Director of Gynecologic Oncology for the Mount Sinai Health System

2. Disclosures
• No financial disclosures
• Research collaborations with Roche, Tesaro, Astra Zeneca, Merck
• Will be discussing off label uses of various agents
• (tried something new)

3. SGO 2019 Themes
• 50 years of progress
• Parp inhibitors
• Immunotherapy
• New combinations
• Risk reducing salpingectomy

15. Tolerating PARP inhibitors
• TWIST: PFS without toxicity due to nausea, vomiting and fatigue
• How to tailor dosing
• Good for all ages

17. PARPi after PARPi
• Clinical benefit rate: over 70%
• BRCA mutation carriers: 85%
• Prior exposure to PARPi does not necessarily confer resistance to
future PARPi
• Toxicity after initial PARPi was not associated with toxicity after
second PARPi

18. SGO 2019

19. Different ways of looking at results
• Disease control rate
• Overall survival more important than progression free survival
• Importance of composite endpoints—not only how long, but how
well

47. IOM 2016 Ovarian Cancer:
Evolving Paradigms in Research
and Care

52. Negative trials
• Javelin: PLD +/- avelumab for recurrent ovarian cancer
• PLD +/- trabectedin for recurrent ovarian cancer